Briacell Therapeutics Corp BCTX

$3.95 +0.68 (20.80%)

Valuation

Market cap
34,493,000
Revenue TTM
$0
Net income TTM
$-26,310,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
160,500
Avg volume
108,136
Day's range
$3.30 – $4.08
Shares out
8,732,000
Stochastic %K
89%
Beta
1.26
Analysts
—
Price target
$40.00

Price

Company profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator...

Show more

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. The company is headquartered in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604-921-1810
Website
https://briacell.com
Address
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

Latest news